What do systematic reviews say?

Amlodipine plus standard iron chelation therapy vs standard chelation therapy with or without placebo

• Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 234 participants
  Very low

Aspirin vs placebo

Aspirin showed no clear difference in total mortality compared with placebo (low certainty).

• Antiplatelet agents and anticoagulants for hypertension 2022 · Cochrane Headline outcomes only
  OR 0.97 [0.87, 1.08]
  3 studies · 35794 participants
  Low

Aspirin vs placebo

Aspirin showed no clear difference in cardiovascular mortality compared with placebo (low certainty).

• Antiplatelet agents and anticoagulants for hypertension 2022 · Cochrane Headline outcomes only
  OR 0.98 [0.82, 1.17]
  3 studies · 35794 participants
  Low

Aspirin vs placebo

Aspirin may leads to lower non‐fatal cardiovascular events compared with placebo (low certainty).

• Antiplatelet agents and anticoagulants for hypertension 2022 · Cochrane Headline outcomes only
  OR 0.63 [0.45, 0.87]
  1 study · 2540 participants
  Low

Aspirin vs placebo

Aspirin leads to higher major bleedinga compared with placebo (high certainty).

• Antiplatelet agents and anticoagulants for hypertension 2022 · Cochrane Headline outcomes only
  OR 1.77 [1.34, 2.32]
  2 studies · 21330 participants
  High

Aspirin vs placebo

Aspirin may leads to lower all cardiovascular events compared with placebo (low certainty).

• Antiplatelet agents and anticoagulants for hypertension 2022 · Cochrane Headline outcomes only
  OR 0.86 [0.77, 0.96]
  3 studies · 35794 participants
  Low

Summary of findings table ‐ Remifentanil vs diazepam

• Perioperative pharmacological interventions for fetal immobilisation during fetal surgery and invasive procedures 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 50 participants
  Low

Summary of findings table ‐ Remifentanil vs diazepam

• Perioperative pharmacological interventions for fetal immobilisation during fetal surgery and invasive procedures 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 50 participants
  Low

Summary of findings table ‐ Remifentanil vs diazepam

Summary of findings table ‐ Remifentanil may leads to higher surgical assessment/satisfaction score = 1 or 2 (Technically… compared with diazepam (low certainty).

• Perioperative pharmacological interventions for fetal immobilisation during fetal surgery and invasive procedures 2022 · Cochrane Headline outcomes only
  RR 2.88 [1.6, 5.15]
  1 study · 50 participants
  Low

Summary of findings table ‐ Remifentanil vs diazepam

• Perioperative pharmacological interventions for fetal immobilisation during fetal surgery and invasive procedures 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 50 participants
  Low

Summary of findings table ‐ Remifentanil vs diazepam

Summary of findings table ‐ Remifentanil may leads to lower maternal OAA score (observer assessment of alertness/sedation) < 4… compared with diazepam (low certainty).

• Perioperative pharmacological interventions for fetal immobilisation during fetal surgery and invasive procedures 2022 · Cochrane Headline outcomes only
  RR 0.09 [0.01, 0.65]
  1 study · 50 participants
  Low

Summary of findings table ‐ Remifentanil vs diazepam

The review found no eligible studies for this question.

• Perioperative pharmacological interventions for fetal immobilisation during fetal surgery and invasive procedures 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Remifentanil vs diazepam

The review found no eligible studies for this question.

• Perioperative pharmacological interventions for fetal immobilisation during fetal surgery and invasive procedures 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Pharmaceutical policies: effects of regulating drug insurance schemes 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Intervention not reported

• Pharmaceutical policies: effects of regulating drug insurance schemes 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Intervention not reported

• Pharmaceutical policies: effects of regulating drug insurance schemes 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Intervention not reported

• Pharmaceutical policies: effects of regulating drug insurance schemes 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 147 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 208 participants
  Very low